MNMD / MindMed CEO: Psychedelic medicine industry is a 'massive opportunity'

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized An more_horizontal

As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups t more_horizontal

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b s more_horizontal

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that members of the Company's management team will participate in several June investor c more_horizontal

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's proprietary form of R-MDMA, in a model for autism more_horizontal

MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expe more_horizontal

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical more_horizontal

The stock of psychedelics company Mind Medicine Inc. MNMD, +4.82% rose 4% Friday, after the company's Swiss research partners reported positive result more_horizontal